Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Vertex Pharma Stock Surges
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.
53m
on MSN
These Stocks Are Moving the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More
Stocks traded mostly lower on Friday after President Donald Trump followed through on his pledge to enact tariffs on Mexico ...
5h
Vertex Pharmaceuticals Shares Are Up Today: What's Going On?
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...
5h
Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
7h
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
AFP
13h
Vertex Announces FDA Approval of JOURNAVXâ„¢ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
6h
Optimistic Outlook for Vertex Pharmaceuticals: Strong Performance, New Approvals, and Promising Pipeline Drive Buy Rating
Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
9h
Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Apple
JOURNAVX
Food and Drug Administration
Pain management
Wells Fargo
Feedback